U.S. Software Stock News

If you are wondering whether Crown Castle stock is priced attractively right now, the recent mix of short term gains and longer term weakness makes the valuation story especially interesting. The share price closed at US$89.10, with returns of 3.4% over 7 days and 5.1% over 30 days. Year to date the stock is up 0.5%, but down 12.3% over 1 year, 10.2% over 3 years and 38.1% over 5 years. Recent headlines have focused on Crown Castle's position within U.S. telecom infrastructure and how...

If you are wondering whether Arcus Biosciences is reasonably priced or getting ahead of itself, the current share price invites a closer look at what investors may actually be paying for. The stock last closed at US$26.06, with returns of 5.1% over the past 7 days, 13.5% over 30 days, 11.9% year to date, and 220.9% over the last year, which points to a stock that has already seen significant movement. Recent coverage around Arcus Biosciences has focused on its position in the biotech space...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Unsurprisingly, Seagate Technology Holdings plc's ( NASDAQ:STX ) stock price was strong on the back of its healthy...

Investors in Encompass Health Corporation ( NYSE:EHC ) had a good week, as its shares rose 3.4% to close at US$105...

Shareholders might have noticed that Shenandoah Telecommunications Company ( NASDAQ:SHEN ) filed its first-quarter...

Investors who take an interest in Option Care Health, Inc. ( NASDAQ:OPCH ) should definitely note that the Executive VP...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

As you might know, Solaris Energy Infrastructure, Inc. ( NYSE:SEI ) just kicked off its latest quarterly results with...

New Jersey Resources (NJR) has just reported its Q2 2026 results, with Q1 fiscal 2026 revenue at US$604.9 million and EPS of US$1.22 setting the tone for how the year is shaping up for the utility. Over the past few quarters, revenue has ranged from US$298.9 million to US$913.0 million while EPS has moved between a loss of US$0.15 and a high of US$2.04. This gives a clear sense of how earnings and the top line have tracked across different periods. With trailing net margin at 15.2% and the...

If you are wondering whether Upstart Holdings at around US$31.17 is priced for a comeback or still carrying too much risk, the starting point is to understand what the current market value really reflects. The stock has been volatile, with a 5.1% decline over the last 7 days, a 21.9% gain over the last 30 days, a 32.0% decline year to date, and a 39.4% decline over the last year. The 3-year return sits at 121.2%, and the 5-year return at a 65.1% decline. Recent coverage around Upstart often...

In the first quarter of 2026, USA TODAY Co., Inc. reported revenue of US$548.49 million, down from US$571.57 million a year earlier, while turning a prior net loss of US$7.33 million into net income of US$19.89 million. The company credited improved profitability to growing digital revenue, AI-related licensing deals, and subscription gains, and reiterated full-year 2026 guidance calling for flat to slightly lower revenue but higher net income compared with last year. Next, we will examine...

ARK Invest recently acquired over 3 million Intellia Therapeutics shares, worth more than US$43 million. The purchase reflects increased institutional interest in Intellia Therapeutics, which trades under ticker NasdaqGM:NTLA. This transaction follows earlier coverage that focused on Intellia's clinical programs, regulatory updates, and financial position. Intellia Therapeutics focuses on CRISPR/Cas9-based therapeutics, an area that many investors watch closely as gene editing moves from...

Soleno Therapeutics stock overview Soleno Therapeutics (SLNO) has drawn investor attention after recent share performance, with the stock showing a one-month return of 34.01% and a three-month return of 25.64%. See our latest analysis for Soleno Therapeutics. That recent momentum sits against a mixed longer record, with a 34.01% 1 month share price return and 25.64% 3 month share price return contrasting with a 28.21% 1 year total shareholder return decline but a very large 3 year total...

If you are wondering whether Conagra Brands at around US$14 still reflects the underlying business, the current share price alone does not tell the full story. The stock has seen a 1.9% decline over the last week, a 10.9% decline over the last month, and is down 19.1% year to date and 34.9% over the last year, which will naturally raise questions about how the market is assessing its risks and potential. These weaker recent returns sit against a longer backdrop, with the stock down 55.6%...

GeneDx Holdings (WGS) opened Q1 2026 with recent quarterly revenue of US$120.99 million in Q4 2025 and a basic EPS loss of US$0.61, alongside trailing 12 month revenue of US$427.54 million and a basic EPS loss of US$0.73. Over the last year, revenue has moved from US$95.64 million in Q4 2024 to US$120.99 million in Q4 2025, while quarterly EPS has swung between a profit of US$0.38 in Q2 2025 and losses of up to US$0.61. This sets up an earnings story that investors may review in terms of how...

Veeco Instruments Inc. reported first-quarter 2026 results with sales of US$158.34 million, down from US$167.29 million a year earlier, and swung from an US$11.95 million net profit to a US$0.324 million net loss. At the same time, Veeco announced over US$250 million in new orders for systems used in Indium Phosphide laser manufacturing, underlining growing demand from silicon photonics and hyperscale data centers. We’ll now examine how Veeco’s new US$250 million Indium Phosphide laser...

Integer Holdings (NYSE:ITGR) has begun a comprehensive review of its business and capital structure. The Board is assessing options that may include a sale, merger, or other business combination. The review follows heightened external interest in the company and involves financial and legal advisors. The process is focused on assessing ways to maximize value for existing shareholders. Integer Holdings, traded on the NYSE under the ticker ITGR, operates in the medical technology space,...

Tronox Holdings plc recently confirmed a quarterly dividend of US$0.0500 per share payable on July 8, 2026, with both the ex-dividend and record dates set in the past on May 11, 2026. Around the same time, Truist downgraded Tronox to Sell, highlighting concerns about cost pressures and near-term earnings guidance despite the dividend affirmation. With Truist’s downgrade foregrounding near-term earnings pressures, we’ll now examine how this development reshapes Tronox’s existing investment...

If you are wondering whether Keysight Technologies at around US$355.93 is a bargain or already pricing in a lot of optimism, the starting point is to understand what the current valuation is actually implying. The stock has shown strong recent momentum, with returns of 7.1% over 7 days, 22.2% over 30 days, 72.3% year to date, 142.9% over 1 year, 148.9% over 3 years and 156.2% over 5 years. This naturally raises questions about how much upside or risk is now baked into the price. Recent...

CleanSpark (NasdaqCM:CLSK) is accelerating a shift from pure Bitcoin mining toward hosting AI and high performance computing data centers. The company is in advanced talks with a potential investment grade hyperscaler tenant for direct data center capacity. New greenfield AI data center construction is underway in Georgia, backed by CleanSpark’s existing power portfolio. Management is publicly addressing concerns around data center power and water usage as part of this transition. For you...

Investors may be wondering if Prudential Financial at around US$100 a share still offers value, or if most of the opportunity has already been priced in. The stock last closed at US$100.27, with returns of 3.5% over the past week, 2.8% over the past month, 3.7% over the last year and 43.0% over three years. Year to date it is down 11.9% and up 21.6% over five years. Recent headlines have focused on Prudential Financial in the context of broader insurance sector sentiment and changing...

FDA approves Jakafi XR extended-release tablets for myelofibrosis, polycythemia vera and graft-versus-host disease. Jakafi XR offers a once-daily dosing option that differs from existing formulations of ruxolitinib. The approval expands Incyte's Jakafi franchise and broadens its treatment toolkit across several serious blood and immune conditions. For investors watching NasdaqGS:INCY, this latest approval sits at the heart of the company’s core focus in hematology and oncology. Jakafi has...

MSA Safety (MSA) has just opened Q1 2026 earnings season with a run of solid headline figures, capped by Q4 2025 revenue of US$510.9 million and basic EPS of US$2.22. Over recent quarters the company has seen revenue move from US$499.7 million in Q4 2024 to US$421.3 million in Q1 2025 and then back to US$510.9 million in Q4 2025, while quarterly EPS ranged between roughly US$1.51 and US$2.23, setting up a results story where margins and profit quality are front and center for investors. See...